275 related articles for article (PubMed ID: 34646840)
1. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
[No Abstract] [Full Text] [Related]
2. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
[TBL] [Abstract][Full Text] [Related]
3. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
[TBL] [Abstract][Full Text] [Related]
4. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
5. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
6. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.
Exposito L; Sánchez-Piedra C; Vela-Casasempere P; Moreno-Ramos MJ; Campos C; Bohorquez C; Manero J; Calvo-Gutiérrez J; Rodríguez-Lozano C; Ruiz-Montesino D; Busquets N; García-González J; Castrejón I; Alonso F; Bustabad S; Díaz-González F
Eur J Clin Invest; 2024 Feb; 54(2):e14095. PubMed ID: 37715584
[TBL] [Abstract][Full Text] [Related]
7. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
8. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
[TBL] [Abstract][Full Text] [Related]
9. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
10. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
[TBL] [Abstract][Full Text] [Related]
11. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.
Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P; Suissa S
Rheumatology (Oxford); 2020 Apr; 59(4):820-827. PubMed ID: 31504972
[TBL] [Abstract][Full Text] [Related]
13. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
14. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
[TBL] [Abstract][Full Text] [Related]
16. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
[TBL] [Abstract][Full Text] [Related]
17. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis.
Lee BW; Lee JJ; Kim WU
Korean J Intern Med; 2024 May; ():. PubMed ID: 38798047
[TBL] [Abstract][Full Text] [Related]
18. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
[TBL] [Abstract][Full Text] [Related]
20. Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Chakravarty SD; McLean RR; Blachley T; Kawashima T; Lin I; Kavanaugh A; Ogdie A
ACR Open Rheumatol; 2022 May; 4(5):447-456. PubMed ID: 35218320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
